View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Frontken Corporation Berhad: 1 director

A director at Frontken Corporation Berhad sold 10,000,000 shares at 0.000MYR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...

PECO Energy Company: Update to credit analysis

PECO's credit reflects its low-risk T&D operations and supportive regulatory environment, offset by high capital expenditures and the potentially lower metrics due to the corporate AMT.

 PRESS RELEASE

Form 8.3 - UK Commercial Property REIT Limited

Form 8.3 - UK Commercial Property REIT Limited 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)   Full name of discloser:Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)   Name of offeror/offeree in relation to whose relevant securitie...

 PRESS RELEASE

Travis Perkins: Director/PDMR Shareholding

Travis Perkins (TPK) Travis Perkins: Director/PDMR Shareholding 13-May-2024 / 14:33 GMT/BST The Company was notified on 10th May 2024, of the purchase of ordinary shares of 11.205105 pence each in the Company on 10th May 2024 by Nick Roberts (a PDMR) under the Company’s BAYE scheme as set out below.   Name Number of Shares Purchased Price Nick Roberts 18 £8.268583 This Notification is made in accordance with the requirements of Article 19 of the UK Market Abuse Regulation, the Notification of Dealing Form for the PDMR can be found below.For further information please ...

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporat...

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporation 13-May-2024 / 14:32 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a tr...

 PRESS RELEASE

EQS-News: Annual General Meeting approves dividend of EUR 1.20 per sh...

EQS-News: Siltronic AG / Key word(s): AGM/EGM Annual General Meeting approves dividend of EUR 1.20 per share 13.05.2024 / 15:36 CET/CEST The issuer is solely responsible for the content of this announcement. Press release Siltronic AG Einsteinstraße 172 81677 Munich Annual General Meeting approves dividend of EUR 1.20 per share Munich, May 13, 2024 – At today's Annual General Meeting of Siltronic AG, the Executive Board and Supervisory Board looked back on a challenging financial year 2023. The continued weak demand, mainly due to increased inventories and the associ...

 PRESS RELEASE

EQS-News: Hauptversammlung beschließt Dividende von EUR 1,20 je Aktie

EQS-News: Siltronic AG / Schlagwort(e): Hauptversammlung Hauptversammlung beschließt Dividende von EUR 1,20 je Aktie 13.05.2024 / 15:36 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung Siltronic AG Einsteinstraße 172 81677 München Hauptversammlung beschließt Dividende von EUR 1,20 je Aktie München, 13. Mai 2024 – Auf der ordentlichen Hauptversammlung der Siltronic AG am heutigen Tag blicken Vorstand und Aufsichtsrat auf ein herausforderndes Geschäftsjahr 2023 zurück. Die anhaltende Nachfrageschwäche, vor allem bedi...

 PRESS RELEASE

Form 8.3 - Tritax Big Box Reit Plc

Form 8.3 - Tritax Big Box Reit Plc 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)   Full name of discloser:Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)   Name of offeror/offeree in relation to whose relevant securities this form ...

Hubei Goto Biopharm Co. Ltd.: 1 director

A director at Hubei Goto Biopharm Co. Ltd. sold 708,700 shares at 21.783CNY and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...

Partners Group Holding AG: 1 director

A director at Partners Group Holding AG sold 3,200 shares at 1,254.962CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...

Scandinavian Tobacco Group AS: 2 directors

Two Directors at Scandinavian Tobacco Group AS sold 50,005 shares at 102.710DKK. The significance rating of the trade was 86/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Hankook Tire & Technology Co., Ltd. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 7 May 2024 in which Moody's reassessed the appropriateness of the ratin...

 PRESS RELEASE

Form 8.3 - Mattioli Woods

Form 8.3 - Mattioli Woods 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)   Full name of discloser:Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)   Name of offeror/offeree in relation to whose relevant securities this form relates: ...

 PRESS RELEASE

Form 8.3 - Lok’n Store Group PLC

Form 8.3 - Lok’n Store Group PLC 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)   Full name of discloser:Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)   Name of offeror/offeree in relation to whose relevant securities this form re...

 PRESS RELEASE

Tilfredsstillende 1. kvartal 2024 i GrønlandsBANKEN

Tilfredsstillende 1. kvartal 2024 i GrønlandsBANKEN Tilfredsstillende 1. kvartal 2024 i GrønlandsBANKEN GrønlandsBANKENs resultat før skat lyder på kr. 61,8 mio. for første kvartal af 2024, mod kr. 49,4 mio. i første kvartal af 2023. Resultatet før kursreguleringer og nedskrivninger udgør tilfredsstillende kr. 61,7 mio. mod kr. 48,5 mio. året før. Udlån er steget med kr. 79 mio. siden udgangen af 2023, og udgør kr. 4.892 mio. ved første kvartals udgang. Stigning i netto rente- og gebyrindtægter i 1. kvartal af 2024 på kr. 15,6 mio. til kr. 119,6 mio. kr. sammenlignet me...

 PRESS RELEASE

Satisfactory Q1 for the BANK of Greenland

Satisfactory Q1 for the BANK of Greenland Satisfactory Q1 for the BANK of Greenland The BANK of Greenland’s profit before tax amounts to DKK 61.8 million for Q1 2024, compared to DKK 49.4 million for Q1 2023. The profit before value adjustments and write-downs is satisfactory at DKK 61.7 million, compared to DKK 48.5 million for the previous year. Lending has increased by DKK 79 million since the end of 2023, amounting to DKK 4,892 million at the end of Q1. Net interest and fee income increased by DKK 15.6 million to DKK 119.6 million in Q1 2024 compared to the same peri...

 PRESS RELEASE

Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented i...

Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress Analyses of SEQUOIA-HCM Elaborate on Dosing and Measures of Safety During Treatment with Aficamten Results from Cardiopulmonary Exercise Testing Showed Improvement in Exercise Performance were Strongly Correlated to Other Measures of Clinical Improvement Company to Host Investor Event and Webcast Today at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOB...

 PRESS RELEASE

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in L...

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine Statistically Significant and Clinically Meaningful Improvements Observed in Primary Efficacy Endpoint and All Secondary Endpoints; Results Consistent Across All Prespecified Subgroups Rapid and Sustained Improvements Observed in Symptoms and Function; No Treatment Interruptions Due to Low LVEF Company to Host Investor Event and Webcast Today at 4:00 PM Western E...

Pepco Holdings, LLC: Update to credit analysis

Our credit view of this issuer reflects its significant regulatory diversity, supported by its credit supportive regulatory environments, offset by its large capital program.

 PRESS RELEASE

Form 8.3 - GCP Asset Backed Income Fund Limited

Form 8.3 - GCP Asset Backed Income Fund Limited 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)   Full name of discloser:Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)   Name of offeror/offeree in relation to whose relevant securiti...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch